Lack of Efficacy Data in Prior Art Dooms PTAB’s Unpatentability Finding for Method of Cancer Treatment Claims

Oct 10, 2019

Reading Time : 2 min

The patent at issue is directed to a method of treating non-small cell lung cancer (NSCLC) by administering erlotinib, a compound that inhibits the epidermal growth factor receptor (EGFR). The patentability of several of the patent claims were challenged in an inter partes review petition, which the Board instituted. The Board ultimately found the challenged claims obvious over two prior art combinations. According to the Board, the combination of prior art references Schnur and Gibbs or Schnur and Patent Owner’s Form 10-K rendered the claims obvious.

On appeal, the Federal Circuit reversed, concluding that the Board’s finding of a “reasonable expectation of success” was not supported by substantial evidence.

As an initial matter, the court held that the Board misinterpreted one of the asserted references, Gibbs, when it found that Gibbs disclosed a “clear inference” that “erlotinib has anti-cancer activity against [NSCLC].” In reaching its decision, the court faulted the Board for failing to carefully consider the two internal references cited in Gibbs to support the statement in Gibbs that compounds have anti-cancer activity in patients with NSCLC. Only one of the two references even mentions NSCLC, but it does not mention erlotinib at all. Thus, properly “[r]eading Gibbs in the context of its cited articles,” the court explained, “reveals that this statement cannot be referring to erlotinib.” The court also faulted the Board for not properly considering a declaration submitted by Dr. Gibbs himself stating he was not aware of a publication discussing erlotinib’s effect on NSCLC at the time Gibbs was published.

Next, the court addressed the Board’s finding that the asserted combinations would have provided a person of ordinary skill with a reasonable expectation of success in using erlotinib to treat NSCLC. In rejecting that determination, the court pointed out that the asserted references “contain no data or other promising information regarding erlotinib’s efficacy in treating NSCLC.” Specifically, the court found that while Schnur broadly discloses over a hundred compounds for treating 12 different types of cancer, it “fails to disclose any in vitro or in vivo efficacy data for erlotinib or otherwise suggest the use of erlotinib to treat NSCLC.” The court further noted that Gibbs fails to cure these deficiencies because it only discloses that erlotinib inhibits the EGFR and has good anti-cancer activity only in certain cancers, not including NSCLC. Regarding Patent Owner’s Form 10-K, the court explained that although the 10-K states that erlotinib had completed Phase I clinical trials, “nothing in [Patent Owner’s] 10-K suggest[s] the existence of erlotinib preclinical efficacy data that is specific to NSCLC.” Finally, given the undisputed fact that NSCLC is highly unpredictable with an over 99.5 percent failure rate for drugs entering Phase II clinical studies, the court concluded that the asserted references “provide no more than hope—and hope that a potentially promising drug will treat a particular cancer is not enough to create a reasonable expectation of success.”

OSI Pharms., LLC v. Apotex Inc., No. 2018-1925, slip op. (Fed. Cir. Oct. 4, 2019)

Practice Tip: In defending against an obviousness challenge to method of treatment claims reciting efficacy, a patent owner should carefully assess whether the asserted references provide any in vitro or in vivo data showing the claimed method is efficacious. If the references lack efficacy data, the patent owner should point to that omission in arguing no “reasonable expectation of success.” A patent owner should also consider bolstering its argument by submitting evidence of clinical trial failures to show the unpredictability of the claimed treatment method.

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.